As dengue cases surge worldwide, India is moving closer to launching a potential breakthrough vaccine. An indigenous vaccine candidate has entered the final stage of clinical testing, raising hopes for one of the world’s first single-dose dengue vaccines. With infections rising sharply due to climate change and rapid urbanisation, public health experts say a safe and effective vaccine could significantly reduce severe cases and deaths.
Global Dengue Surge Raises Urgency
Dengue, a mosquito-borne viral disease, causes high fever, intense body aches, and in severe cases, life-threatening complications such as dengue hemorrhagic fever. According to the World Health Organization (WHO), nearly half of the global population is now at risk of dengue infection. The agency estimates between 100 and 400 million infections occur every year. In India alone, more than one million dengue cases and at least 1,500 deaths have been recorded since 2021, highlighting the urgent need for preventive solutions.
Panacea Biotec’s DengiAll Enters Final Testing Stage
Indian pharmaceutical company Panacea Biotec has initiated Phase III clinical trials of its dengue vaccine candidate, DengiAll, after nearly 15 years of research and development. The large-scale trial, which began in 2024, involves over 10,000 volunteers across India. The study is being overseen by the Indian Council of Medical Research (ICMR), ensuring regulatory and scientific oversight. If results are favourable, the vaccine could be rolled out as early as next year. “We will try to get this vaccine out there as soon as possible,” said Syed Khalid Ali, Chief Scientific Officer of Panacea Biotec.
Why Dengue Vaccine Development Is Challenging
Developing a dengue vaccine has historically posed significant scientific challenges. The virus exists in four distinct serotypes, and immunity to one does not guarantee protection against the others. In fact, secondary infections can sometimes be more severe. Currently, most dengue vaccine candidates require multiple doses for effectiveness. DengiAll is based on a tetravalent strain originally developed by the US National Institutes of Health and is designed to protect against all four serotypes with a single dose. If approved, it would become one of the world’s first single-dose dengue vaccines, following Brazil’s approval of a similar vaccine last year. Importantly, India currently has no licensed dengue vaccine for public use.
Hyperendemic Situation in India
Experts warn that dengue has become hyperendemic in India, with all four virus serotypes circulating simultaneously. Dr. Ekta Gupta, Professor of Clinical Virology at the Institute of Liver and Biliary Sciences in New Delhi, stressed the urgency of vaccination. “This vaccine is very much needed right now to control the occurrence of these cases, or at least prevent the severity,” she said. Monsoon outbreaks routinely overwhelm hospitals, particularly in densely populated urban centres. Meanwhile, rural regions often struggle with delayed diagnosis and limited access to advanced care. Children remain particularly vulnerable to severe dengue complications due to risks such as low platelet counts and shock.
Climate Change Driving Dengue Spread
Rising temperatures and changing rainfall patterns have created ideal breeding conditions for Aedes mosquitoes, the primary carriers of the dengue virus. Public health researchers warn that if current climate change trends continue, dengue incidence could increase by 50–75 percent by 2050. As mosquito habitats expand geographically, new populations may become vulnerable to outbreaks.
Safety, Regulation and Next Steps
Inside Panacea’s research laboratories, scientists continue to prioritise safety and regulatory compliance. Dr. Priyanka Priyadarsiny, Head of Biological R&D at Panacea, emphasised the rigorous evaluation process. “We are extremely cautious about purity, safety and adverse effects. Only after meeting regulatory specifications can a product be considered safe for public use,” she said. Participants in the Phase III trial have been randomly assigned either the vaccine or a placebo. Final results are expected later this year. If successful, approval in India would come from the Drug Controller General of India. For international distribution, WHO prequalification would be required. At present, the WHO recommends only one dengue vaccine — Qdenga, developed by Japan’s Takeda Pharmaceutical Company — for children aged six to 16 in high-transmission settings. However, Qdenga requires two doses and is not currently available in India.
Hope for Affordable Global Access
As reported by etvbharat.com, experts believe that a successful Indian-made dengue vaccine could significantly improve affordability and access, particularly in lower- and middle-income countries. While virologists caution that final Phase III data will determine the vaccine’s safety and efficacy, optimism remains high. “Phase III testing and follow-up are needed to show if the criteria are met,” said Oxford University fellow Shahid Jameel. “Only then can we have a useful dengue vaccine. It is still early days, but there is hope for the future.” If approved, DengiAll could mark a turning point in global dengue prevention — offering a scalable, single-dose solution at a time when the world urgently needs it.